Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193294 | 1.00 | LMNA (0.68) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL386229 | 1.00 | LMNA (0.68) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL632397 | 0.94 | LMNA (0.68) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL3337422 | 0.89 | LMNA (0.68) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL7269036 | 0.86 | LMNA (0.74) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL10945252 | 0.86 | LMNA (0.74) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL10991364 | 0.85 | LMNA (0.53) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL20928 | 0.85 | LMNA (0.93) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL538230 | 0.85 | LMNA (0.93) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL8672325 | 0.85 | LMNA (0.93) | LMNABLMMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322695-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY | 2023-10-12 | — | — | US | claimed |
| WO-2023147531-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-03 | — | — | WO | claimed |
| CN-110268066-B | Enzymatic reaction medium containing surfactant | 诺华股份有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2018134710-A1 | ENZYMATIC REACTION MEDIUM CONTAINING SURFACTANT | NOVARTIS AG (CH) | 2018-07-26 | — | — | WO | claimed |
| CN-103732676-B | What have excellence is the polyolefin compositions for tubing of color stability and thermostability and scale resistance | 北欧化工股份公司 | 2016-06-15 | — | — | CN | claimed |
| EP-2551297-B1 | Polyolefin composition with excellent colour and thermal stability as well as oxidation resistance for pipes | BOREALIS AG (AT) | 2014-03-12 | — | — | EP | claimed |
| WO-2013013805-A1 | POLYOLEFIN COMPOSITION WITH EXCELLENT COLOUR AND THERMAL STABILITY AS WELL AS OXIDATION RESISTANCE FOR PIPES | BOREALIS AG (AT) | 2013-01-31 | — | — | WO | claimed |
| EP-2551297-A1 | Polyolefin composition with excellent colour and thermal stability as well as oxidation resistance for pipes | Borealis AG (AT) | 2013-01-30 | — | — | EP | claimed |
| CN-101680124-B | High tenacity polyethylene yarn | HONEYWELL INT INC | 2012-09-05 | — | — | CN | claimed |
| CN-101680124-A | High tenacity polyethylene yarn | HONEYWELL INT INC | 2010-03-24 | — | — | CN | claimed |
| EP-1013652-B1 | Process for preparation of substituted chromanderivatives | BASF AG (DE) | 2002-08-14 | — | — | EP | claimed |
| JP-2001526219-A | — | — | 2001-12-18 | — | — | JP | claimed |
| US-6136985-A | COMPRISING CONJUGATED LINOLEIC ACID ESTERS SUCH AS TOCOPHERYL ESTER, ASCORBYL ESTERS; IN COSMETICS FOR TOPICAL USE; INHIBITS EPIDERMAL CARCINOGENESIS | DCV, INC. (US) | 2000-10-24 | — | — | US | claimed |
| EP-1041979-A1 | ESTERS OF CONJUGATED LINOLEIC ACID OR CONJUGATED LINOLENIC ACID AND USES THEREOF | DCV Inc. doing business as Bio-Technical Resourses (US) | 2000-10-11 | — | — | EP | claimed |
| EP-1013652-A2 | Process for preparation of substituted chromanderivatives | BASF AKTIENGESELLSCHAFT (DE) | 2000-06-28 | — | — | EP | claimed |
| EP-0188079-B1 | USE OF TOCOPHERYL GLYCOSIDES FOR ACTIVATING THE FUNCTION OF PHAGOCYTES | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1992-04-08 | — | — | EP | claimed |
| EP-0169716-B1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING ANTIALLERGIC ACTIVITY | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1991-10-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | LMNA 344/4885BLM 1854/4885MEN1 1711/4885 |
| US-20230322695-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | PTPN2, PTPN22, PTPN5 | LMNA 4590/4885BLM 2909/4885MEN1 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.